36 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.
30 citations
,
April 2007 in “Dermatologic Clinics” This review discusses the mechanisms by which isotretinoin and hormonal therapy treat acne through their effects on sebaceous glands, reporting no new clinical results.
22 citations
,
September 2015 in “Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia” This review describes the various cutaneous manifestations of essential thrombocythemia and how treatments like hydroxycarbamide, interferon-alfa, and anagrelide may lead to skin complications, but does not report new clinical findings.
15 citations
,
April 2020 in “Journal of The American Academy of Dermatology” This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.
14 citations
,
April 2019 in “International Journal of Women's Health” This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.
11 citations
,
March 2021 in “Dermatology and therapy” This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.
9 citations
,
October 2020 in “Journal of The American Academy of Dermatology” This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.
7 citations
,
August 2013 in “Facial Plastic Surgery Clinics of North America” This review discusses the indications and technical aspects of megasession hair transplantation and reports no new clinical results.
4 citations
,
August 2001 in “Epilepsia” This narrative review discusses issues in the treatment of epilepsy, focusing on antiepileptic drug compliance, side effects, and the challenges of drug selection; it reports no new clinical findings.
3 citations
,
November 2020 in “Clinical, Cosmetic and Investigational Dermatology” This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” This report shares the authors' experience using spironolactone for treating acne in a PCOS clinic, but provides no new clinical results.
2 citations
,
July 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” This study observed that both SARS-CoV-2 and other acute respiratory infections are linked to a wide range of long-term symptoms, highlighting the need to investigate post-acute sequelae beyond COVID-19.
1 citations
,
January 2016 in “ARC Journal of Urology” This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.
1 citations
,
September 2023 in “Journal of drugs in dermatology” This article discusses the perspectives of clinicians and patients on alopecia areata, an autoimmune disorder with significant psychosocial impacts, highlighting the unpredictability and limited effectiveness of current treatments as well as the key unmet needs and gaps in care.
In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.
April 2016 in “Journal of Urology and Nephrology Open Access” This abstract discusses treatment options for benign prostatic hyperplasia and provides no new clinical results.
June 2026 in “Discover Nano” This review discusses current treatment strategies for alopecia and highlights the potential of lipid-based nanoparticles to improve drug delivery to the scalp and hair follicles, noting their ability to enhance skin penetration and drug stability while outlining associated challenges and the need for further research.
January 2026 in “Frontiers in Pharmacology” This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.
May 2025 in “Journal of Drug Delivery and Therapeutics” This review discusses the integration of modern and Unani medicine in the management of Benign Prostatic Hyperplasia, highlighting the potential of Unani herbal formulations as promising alternatives with minimal side effects but reports no new clinical results.
This study observed that both intradermotherapy with 5% minoxidil and topical minoxidil application resulted in perceived improvements in hair density and thickness among patients with androgenetic alopecia, with no significant difference between the two groups.
This study reviews 10 herbal supplements, including Berberine and Cinnamon, as alternative treatments for PCOS, noting they are more accessible and affordable than conventional medications, especially in low-resource settings, though further clinical research is needed.
January 2025 in “Annals of Dermatology” This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
January 2025 in “Medical Research Archives” In this review, researchers reported that anorexia nervosa leads to widespread medical complications across all body systems, particularly at low body weights, and these complications are primarily treated through nutritional rehabilitation with a multidisciplinary team approach.
November 2024 in “EMJ Dermatology” In clinical studies, inhibiting androgen receptor expression using CosmeRNA ARI SAMiRNA micelles effectively treated androgenetic alopecia by significantly increasing hair growth, as reported in this research.
March 2024 in “Cleveland Clinic journal of medicine” This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.
This review of Lawsonia inermis L., or henna, details its bioactive compounds and historical uses in Unani medicine, including treatment for various conditions like ulcers and jaundice, while highlighting its potential for wound healing, hepatoprotective, and other effects, though further research is needed.
September 2023 in “Translational medicine reports” This case study reported that an 18-year-old woman ingested a large amount of topical minoxidil, leading to symptoms like low blood pressure, increased heart rate, and elevated liver enzymes, but recovered fully after treatment. Minoxidil toxicity may rarely cause abnormal liver enzyme levels.
September 2023 in “Deleted Journal” This study, conducted at the Surgical Outpatient Clinics of the Medical Research Institute in Alexandria, Egypt, found that post-bariatric surgery patients commonly experienced gastrointestinal and dermatological issues, fatigue, impaired physical activity, and psychological conditions like anxiety within the first year after surgery.
January 2023 in “International Journal of Research Publication and Reviews” This review details the causes, symptoms, and treatments for dandruff, emphasizing herbal ingredients with anti-dandruff properties used in shampoos and exploring their antifungal and anti-inflammatory mechanisms. It highlights dandruff's exploitation by personal care companies due to the lack of medical interventions.
December 2022 in “Sudan Journal of Medical Sciences” This review paper discusses the effectiveness of repurposed drugs and potential novel therapies for treating COVID-19, highlighting remdesivir as the only FDA-approved medication and listing others with Emergency Use Authorization.